[Trial of a new therapeutic agent, Pervincamine, in the post-concussion syndrome of patients with head injuries. Application of a double-blind control system and sequential analysis].
The authors have studied the influence of Pervincamine on the postconcussional syndrome in a group of 30 patients with cranial trauma examined for at least six months after their accident. The double blind testing was utilised and the patients were followed at regular intervals spanning three weeks. Each patient was evaluated by semi-directed interviews and tests of "double barrage" of Zazzo and the 15 words test of Rey. In addition, an EEG was performed at the beginning and the end of the study. Statistical analysis of the evolution of symptoms and the results obtained by psychological testing has revealed the positive action of Pervincamine on the postconcussional syndrome and on mental as well as motor functioning in general. Furthermore, the secondary effects of this product are negligible.
D000293:Adolescent; D000328:Adult; D001924:Brain Concussion / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004569:Electroencephalography; D005260:Female; D006801:Humans; D008297:Male; D008568:Memory; D008875:Middle Aged; D010919:Placebos; D013577:Syndrome; D013997:Time Factors; D014748:Vinca Alkaloids / Q000627:therapeutic use*
D010919:Placebos; D014748:Vinca Alkaloids
Essai d'un nouvel agent thérapeutique, la pervincamine, dans le syndrome postcommotionnel des traumatisés crâniens. Application d'une méthode de contrôle à double anonymat et de l'analyse séquentielle